Californian biotech, Claritas Pharmaceuticals, is expanding its R-107 development program to include the treatment of COVID-19 related sepsis (the leading cause of death in COVID-19 patients).
The expansion is based on “significantly positive” results in a controlled large animal model of sepsis.
“The data we are announcing today demonstrate that R-107 significantly reduced mortality in an aggressive and clinically-predictive animal model of sepsis. The importance of these data cannot be overstated,” said Robert Farrell, Claritas’ President and CEO.
“While bacterial sepsis may be treated with antibiotics, this is not the case with COVID-19 viral sepsis.
“Approved therapies, such as remdesivir, dexamethasone and bamlanivimab, are helpful for patients with mild illness, but are not particularly effective in COVID-19 patients who have developed sepsis.
“ For COVID-19 patients who have developed sepsis, there are few available therapies beyond supportive care.”
He added: “Our data unequivocally demonstrate that R-107 treatment reduced mortality in a controlled study in a large animal model of sepsis.
“We are aware of no other drug that is marketed or in development that has achieved superior results in this animal model of the disease.”